Study of an inhibitor of plasminogen activator (tranexamic acid) in the treatment of experimental osteoarthritis.
The effects of tranexamic acid, an inhibitor of plasminogen activator, were evaluated in a rabbit model of osteoarthritis induced by section of the knee joint anterior cruciate ligament. Prophylactic treatment administered intramuscularly thrice weekly for 12 or 24 weeks significantly reduced cartilage destructive lesions, increased cartilage hypertrophy but did not prevent changes in cartilage water and proteoglycan content. A suppression of synovial membrane stromelysin and collagenase activity was found while phospholipase A2 activity was unaffected.
Vignon
E
E
Department of Rheumatology and Biochemistry, E. Herriot Hospital, Claude Bernard University, Lyon, France.
Mathieu
P
P
Bejui
J
J
Descotes
J
J
Hartmann
D
D
Patricot
L M
LM
Richard
M
M
D000818:Animals; D002358:Cartilage, Articular / Q000187:drug effects / Q000473:pathology; D004195:Disease Models, Animal; D005260:Female; D006984:Hypertrophy / Q000188:drug therapy / Q000473:pathology; D007273:Injections, Intramuscular; D007719:Knee Joint / Q000187:drug effects / Q000473:pathology; D019278:Matrix Metalloproteinase 3; D008666:Metalloendopeptidases / Q000378:metabolism; D003012:Microbial Collagenase / Q000378:metabolism; D010003:Osteoarthritis / Q000188:drug therapy* / Q000473:pathology; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors; D015849:Plasminogen Inactivators; D011817:Rabbits; D013583:Synovial Membrane / Q000187:drug effects / Q000378:metabolism; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D015849:Plasminogen Inactivators; D014148:Tranexamic Acid; D010741:Phospholipases A; D054467:Phospholipases A2; D010960:Plasminogen Activators; D008666:Metalloendopeptidases; D019278:Matrix Metalloproteinase 3; D003012:Microbial Collagenase